EMA Schedules High-Stakes Oral Explanation Meeting For Aducanumab Filing

The sponsors of aducanumab and three other drugs are set to explain why their EU marketing authorization applications merit approval during oral explanation meetings at the European Medicines Agency.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
Aducanumab is at the latter stages of the EMA's regulatory review cycle • Source: Alamy

Aducanumab, the Alzheimer’s disease drug from Biogen and Eisai that was controversially approved in the US in June, is among four products nearing the end of the EU marketing review cycle that the European Medicines Agency has scheduled for an oral explanation meeting this week.

The oral explanation meeting for aducanumab (US brand name Aduhelm) was due to take place on 9 November, according to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography